Background & Aims Tumor necrosis factor inhibitors, including infliximab and adalimumab,
are a mainstay of pediatric Crohn’s disease therapy; however, nonresponse and loss of …

Objective. Accumulating evidence links juvenile idiopathic arthritis (JIA) to nonhost factors
such as gut microbes. We hypothesize that children with new-onset JIA have increased …

Objectives: Variations in chronic illness care are common in our health care system and
may lead to suboptimal outcomes. Specifically, inconsistent use and suboptimal medication …

Objectives To evaluate whether Patient-Reported Outcomes Measurement Information
System (PROMIS) pediatric patient-reported outcome (PRO) measures can serve as valid …

BACKGROUND/AIMS: The cirrhotic liver manifests dysregulated hepatocyte growth by poor
regenerative capacity, formation of regenerative nodules, and malignant transformation to …

Background: Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and
subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 …

The recent changes in Capricorn Education District have placed new external pressures on
secondary school principals. The implementation of the new curriculum policy is fraught with …

Objectives: The aim of the study was to use pharmacy benefit management (PBM) prescription
claims data to assess refill adherence in pediatric inflammatory bowel disease (IBD) and …

Background. During hepatic regeneration, transforming growth factor (TGF)-β1 messenger
RNA increases after the initial cycle of DNA synthesis, and it may control hepatocyte growth …

INTRODUCTION: Cholestasis activates nuclear factor kappa B (NFκB), which is involved in
both hepatocyte proliferation and apoptosis, depending on the cellular microenvironment. …